ArriVent BioPharma (AVBP) had its price target raised by HC Wainwright from $42.00 to $44.00. They now have a "buy" rating on the stock.
ArriVent BioPharma Reports Full Year 2025 Financial Results [Yahoo! Finance]
ArriVent BioPharma Reports Full Year 2025 Financial Results
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight